The US pharmaceutical company Gilead has created the antiviral medication Lenacapavir, which has been heralded as a potential game-changer in the fight against HIV.
According to early trials, the therapy is 100% successful in avoiding HIV infection. Furthermore, the medicine is far simpler to give than existing regimens needing daily pills because it only needs to be injected twice a year.
Liverpool University researcher Andrew Hill remarked, “It’s basically like having a vaccine.”
Patients in a number of nations, including Australia, France, Norway, and the United States, currently pay more than $40,000 annually for the treatment.
Hill discussed new findings at the International Aids Conference in Munich on Tuesday. The research examined potential reductions in the drug’s manufacturing costs.
